Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20206 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Jong Wook Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Anemia, Aplastic, Recombinant Fusion Proteins, Cyclosporine, Thrombopoietin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kyowa Kirin.
Abstract (Originalsprache)
Romiplostim has been shown to restore multi‐lineage haematopoiesis and is effective in patients with aplastic anaemia (AA) refractory to immunosuppressive therapy (IST). This open‐label, phase 2/3 study (NCT04095936) recruited adult AA patients in Japan and Korea who had not received prior IST and evaluated the efficacy and safety of romiplostim plus ciclosporin A (CsA). Romiplostim was initiated at 10 μg/kg once weekly through Week 4 and adjusted between 0 and 20 μg/kg from Week 5 onwards. CsA was administered at 5–6 mg/kg/day in two divided doses through Week 26. A total of 24 patients (median [range] age, 52 [19–80] years) were enrolled, and 22 (91.7%) completed the study. Four patients (16.7%) had very severe AA (VSAA), 13 (54.2%) had severe AA (SAA) and seven (29.2%) had transfusion‐dependent non‐severe AA (NSAA). A haematological response at Week 27 was observed in 10/24 patients (overall response, 41.7%; 95% confidence interval, 22.1%–63.4%). At Week 27, the subgroup overall response rates were 0.0% in VSAA, 46.2% in SAA and 57.1% in NSAA. Nearly 92% of patients experienced at least one treatment‐emergent adverse event (TEAE), but no drug‐related Grade ≥3 TEAEs were reported. One patient developed myelodysplastic syndromes. Treatment with romiplostim plus CsA was effective and well tolerated in patients with AA who had not previously received IST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea.
- Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Hematology, University of Tsukuba, Tsukuba, Japan.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Hematology, Japan Red Cross Musashino Hospital Tokyo, Tokyo, Japan.
- Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
ORCID-Profile: Jun Ho Jang, Shigeru Chiba, Shinji Nakao
Förderung
- Kyowa Kirin
Zitieren
APA
Lee, J. W., Jang, J. H., Chiba, S., Yoon, S. S., Oshikawa, G., Usuki, K., Mun, Y. C., Kawakita, T., Imada, K., Cheong, J. W., Noshiro, M., Matsuda, A., Ozawa, K., Mitani, K., Kanda, Y., & Nakao, S. (2025). Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study. British Journal of Haematology. https://doi.org/10.1111/bjh.20206
Vancouver
Lee JW, Jang JH, Chiba S, Yoon SS, Oshikawa G, Usuki K, et al. Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study. British Journal of Haematology. 2025. doi:10.1111/bjh.20206
BibTeX
@article{Lee2025,
author = {Lee, Jong Wook and Jang, Jun Ho and Chiba, Shigeru and Yoon, Sung-Soo and Oshikawa, Gaku and Usuki, Kensuke and Mun, Yeung-Chul and Kawakita, Toshiro and Imada, Kazunori and Cheong, June-Won and Noshiro, Masayoshi and Matsuda, Akira and Ozawa, Keiya and Mitani, Kinuko and Kanda, Yoshinobu and Nakao, Shinji},
title = {Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20206}
}
EUVIMED